Comparison of trends in prostate-cancer mortality in England and Wales and the USA

Lancet

Volumn 355, Issue 9217, 2000, Pages 1788-1789

  Oliver, E ^a   Gunnell, D ^a   Donovan, J L ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SECONDARY PREVENTION; UNITED KINGDOM; UNITED STATES;

EID: 0343092033     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02269-8     Document Type: Article

References (5)

1. Mettlin C.J., Murphy G.P. Why is the prostate cancer death rate declining in the United States? Cancer. 82:1998;249-251.
2. Ries L.A.G., Kosary C.L., Hankey B.F., Miller B.A., Clegg L., Edwards B.K. SEER cancer statistics review, 1973-1996. 1999;National Cancer Institute, Bethesda.
3. Legler J.M., Feuer E.J., Potosky A.L., Merrill R.M., Kramer B.S. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control. 9:1998;519-527.
4. Chamberlain J., Melia J., Moss S., Brown J. Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol. 79(suppl 3):1997;1-32.
5. Donovan J.L., Frankel S.J., Faulkner A., Selley S., Gillatt D., Hamdy F.C. Dilemmas in treating early prostate cancer. the evidence and a questionnaire survey of consultant urologists in the United Kingdom BMJ. 318:1999;299-300.